Ascletis Pharma Inc. said CFO Lindi Tan left the company on Sept. 30, after joining less than one year ago.
The company did not name a reason for her departure. It appointed Tan as CFO in November 2018.
Ascletis Pharma said it hired Ernst & Young as its external auditor to conduct audits and assist the audit committee on its financial review and other related matters.
The Hangzhou-based company's Chief Medical Officer Li Zhengqing also left in July due to family and health reasons after less than six months in the role.
Ascletis Pharma develops therapies for viral diseases, cancer and fatty liver diseases.
